We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UCB announced an agreement to enter into a world-wide, exclusive license agreement with Roche and Genentech, a member of the Roche Group, for the global development and commercialization of UCB0107 in Alzheimer's Disease (AD).
Roche and its unit Genentech have agreed to a global, exclusive licence agreement with Belgian company UCB to develop and commercialise an antibody treatment, UCB0107, for Alzheimer’s disease.